Didanosine Dosed Once Daily Is Equivalent to Twice Daily Dosing for Patients on Double or Triple Combination Antiretroviral Therapy

OBJECTIVE:To compare the antiviral activity, effect on CD4 cell count, and tolerability of didanosine (ddI) administered once daily and twice daily in HIV-1-infected patients receiving ddI with stavudine or zidovudine, with or without a protease inhibitor. The study was designed to demonstrate that...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of acquired immune deficiency syndromes (1999) 2000-08, Vol.24 (5), p.418-424
Hauptverfasser:	Kazatchkine, M D, Van, Ngo P, Costagliola, D, Mohammed, Si A, Ledeine, J M, Troccaz, M, Belec, L
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Biological and medical sciences Drug therapy Fundamental and applied biological sciences. Psychology HIV Human immunodeficiency virus Human viral diseases Infectious diseases Medical sciences Microbiology Pharmacology. Drug treatments Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	OBJECTIVE:To compare the antiviral activity, effect on CD4 cell count, and tolerability of didanosine (ddI) administered once daily and twice daily in HIV-1-infected patients receiving ddI with stavudine or zidovudine, with or without a protease inhibitor. The study was designed to demonstrate that once-daily dosing of ddl was not inferior to twice-daily dosing. DESIGN:Randomized, open-label, multicenter, two-arm study.Patients and Methods121 HIV-1-infected adults on a stable regimen including ddl (twice daily) during the previous 3 months with a stable viral load
ISSN:	1525-4135 1944-7884
DOI:	10.1097/00042560-200008150-00003